New drug shows promise for rare joint tumor in early trial
NCT ID NCT03069469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see how well it shrinks tumors and improves symptoms like pain and joint movement. About 120 adults are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vimseltinib (a drug that blocks a protein called CSF1R, which helps control certain tumor growth)
What this could lead to
If successful, this could provide a new treatment option for people with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery, potentially shrinking tumors and improving joint movement.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leon Berard
Lyon, France
-
Dana Farber
Boston, Massachusetts, 02215, United States
-
Fondazione IRCCS Istituto Nazionale Dei Tumori
Milan, Italy
-
Gustave Roussy Cancer Campus Grand Paris
Paris, France
-
Hospital Clinico San Carlos
Madrid, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario Virgen del Rocío, Sevilla
Seville, Spain
-
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy
-
Istituto Nazionale dei Tumori
Milan, Italy
-
Leiden University Medical Center
Leiden, Netherlands
-
M. Sklodowska-Curie Memorial Cancer Center
Warsaw, Poland
-
MSKCC
New York, New York, 10065, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
McGill University Health Centre
Montreal, Quebec, Canada
-
OHSU
Portland, Oregon, 97239, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Peter MacCallum Cancer Centre
Melbourne, Australia
-
Princess Margaret Cancer Center
Toronto, Canada
-
Regina Elena National Cancer Institute
Rome, Italy
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
University College Hospital
London, United Kingdom
-
University of Colorado - Denver
Denver, Colorado, 80204, United States
-
University of Miami
Miami, Florida, 33136, United States